LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly in Advanced Talks to Acquire Psychedelic Drugmaker AtaiBeckley
Eli Lilly & Co. reportedly holds advanced discussions to acquire psychedelic drug developer AtaiBeckley. A deal announcement could occur as soon as this week....
Novo Nordisk wins EU approval for oral Wegovy, first GLP-1 pill
The European Commission approved Novo Nordisk’s once-daily oral version of Wegovy. This is the first oral GLP-1 treatment for weight management in the European...
Eli Lilly’s Retevmo Wins Full FDA Approval for Advanced Solid Tumors
The U.S. Food and Drug Administration granted full approval to Eli Lilly’s Retevmo on Tuesday for treating advanced solid tumors. The approval applies to adult...
🔴 Eli Lilly is trading 3% down today as CVS Health questions GLP-1 cost-effectiveness
Eli Lilly is trading 3% down at $1146.36 after CVS Health’s pharmacy benefits arm raised concerns over the return on investment for expensive GLP-1 weight-loss...
US Appeals Court Revives Teva Lawsuit Against Eli Lilly Over Forteo
A U.S. appeals court revived a lawsuit from Teva Pharmaceuticals. Teva accuses Eli Lilly of breaching a settlement related to the osteoporosis drug Forteo. The...
Eli Lilly Receives $1,400 Price Target, Fueled by Mounjaro and Zepbound
JPMorgan analyst Chris Schott raised the Eli Lilly price target to $1,400. The previous target was $1,300. Schott reiterated an Overweight rating for the...
Eli Lilly to Unveil New Alzheimer's Data for Donanemab and Advanced Diagnostics at AAIC 2026
Eli Lilly and Company will present 16 research abstracts at the Alzheimer's Association International Conference (AAIC). The conference runs from July 12-15 in...
Lilly's Double Catalyst — Can a $50 Obesity Pill and a Cancer Drug Expansion Justify a Trillion-Dollar Valuation?
Shares of Eli Lilly surged 3.7% to $1,244.16 after two developments landed in quick succession: European regulators endorsed a broader use for the company's...
🟢 LLY is trading 3.7% up today after Medicare pricing deal and Jaypirca label expansion
LLY is trading 3.7% up at $1244.16 following positive regulatory and reimbursement developments for its core drug portfolio. • An EMA panel recommended a...
Eli Lilly eyes $71M Foundayo debut, betting on easier dosing than Wegovy
Jefferies analysts forecast Eli Lilly’s new oral obesity drug, Foundayo, will generate $71 million in U.S. sales for its debut quarter ending June. The FDA...
Eli Lilly Faces US Probe Over China Trials, Shifts Cancer Drug Rights
The U.S. House Select Committee on the Chinese Communist Party is investigating Eli Lilly’s clinical trial activities in China. This bipartisan probe focuses...
🔴 LLY is trading 2.3% down today as investors reassess GLP-1 economics after Medicare's Wegovy pilot
LLY is trading 2.3% down at $1201.96 as investors reassess GLP-1 economics following Medicare’s new Wegovy obesity-drug pilot and broader weight-loss coverage...
Sandoz files for generic Mounjaro and Zepbound, challenging Lilly’s weight-loss lead
The U.S. Food and Drug Administration accepted two applications from Sandoz for generic versions of Eli Lilly’s GLP-1 drugs, Mounjaro and Zepbound. Both...
🟢 LLY extends move to 6.3% up
LLY is trading at $1199.00, up 6.3% versus the comparison close of $1127.69 during regular trading. This is a price-movement alert; no separate...
🟢 LLY up 4.1% today as Eli Lilly's Jaypirca receives positive EU recommendation for CLL
Eli Lilly (LLY) is trading 4.1% up at $1,173.96 today, following a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products...
Eli Lilly offers Zepbound for $50, targeting 20 million Medicare patients
Eli Lilly and Company will launch its Medicare GLP-1 Bridge program on July 1, 2026. Eligible Medicare Part D patients will pay $50 per month for Zepbound...
🟢 LLY is trading 2.2% up today after a $1.9B Abbisko deal and China obesity drug optimism
LLY is trading 2.2% up at $1141.61 following news of a potential $1.9 billion research collaboration with Abbisko Therapeutics. • The partnership is...
Lilly Inks $1.9B R&D Deal, Eyes Late 2026 China Launch for Oral Obesity Drug
Eli Lilly announced a research and development collaboration with Chinese drug developer Abbisko Therapeutics potentially worth up to $1.9 billion. [6, 8]...
Eli Lilly seals $7.8B Centessa acquisition, expanding sleep-wake disorder pipeline
Eli Lilly will finalize its acquisition of Centessa Pharmaceuticals on June 24, 2026. The High Court of Justice of England and Wales has granted final approval...
Eli Lilly Partners with BioArctic in $800M Deal for Neuro-Drug Technology
Eli Lilly entered a research and collaboration agreement with Swedish biopharma firm BioArctic. The partnership combines an undisclosed Lilly drug candidate...